Both APOA1 and APOA2 are discussed as biomarkers and treatment targets in diabetic retinopathy (DR), polypoidal choroidal vasculopathy (PCV), and AMD, although there is no consistency in studies regarding the mechanism of action [48,49,50,51]. The gene discussed is APOA2; the disease is diabetic retinopathy.